The first patient has been enrolled in a global Phase 3 clinical trial evaluating Mocertatug Rezetecan, a novel B7-H4-targeted ADC, in platinum-resistant ovarian cancer. The study aims to determine whether this therapy can improve outcomes compared with standard chemotherapy.
Researchers identify CNTD1 mutations as a cause of diminished ovarian reserve, characterized by reduced ovarian follicles and compromised fertility. The study establishes CNTD1's essential role in maintaining ovarian function and preserving the follicular reserve required for female fertility.
A new study reports that forty percent of women with ovarian cancer only receive a diagnosis after an emergency hospital admission. Women diagnosed through this route are four times more likely to die within two months of diagnosis.
Rates of diagnosis after emergency admission are even higher among women who are young, old, frail, or live in areas of deprivation, findings indicate. Ovarian cancer is the eighth most common female cancer worldwide, taking over 200,000 lives every year.
A recent Estonian study reveals that 19.7% of healthy family members of breast and ovarian cancer patients carry variants that elevate their cancer risk, including 34% of men. The findings highlight the importance of genetic testing and counseling for those with a family history of the disease.
Researchers found that targeting PAK1 enhances therapeutic efficacy of PARP inhibitors in ovarian cancer by impairing DNA repair. Combining olaparib with IPA-3, a PAK1 inhibitor, results in increased tumor cell killing and DNA damage accumulation.
Dr. Dan Landau receives Lotus Award for research on uncovering immunotherapy targets in ovarian cancer. He aims to develop new therapeutic perspectives using single-cell profiling techniques and identify unusual variants of proteins as potential targets.
Researchers at The Wistar Institute and Temple University have identified a metabolic target that can help overcome chemotherapy resistance in ovarian cancer. Elevated alpha-ketoglutarate activates an enzyme called TMLHE, which drives carnitine production and loosens the DNA-histone complex, allowing cells to access and fix damaged DNA.
Dr. Sandra Orsulic has received two federal awards totaling nearly $2 million to advance research aimed at improving outcomes for women with ovarian cancer. Her team will examine the body's inflammatory response after surgery and develop AI-powered tools to guide personalized treatment.
A first-in-human trial demonstrates the potential of implantable cytokine factories for treating ovarian cancer, showing a favorable safety profile and encouraging disease stabilization in patients. The therapy successfully activated key immune cells without expanding regulatory T cells, revealing a promising mechanism of action.
A new study found that a fluid surrounding many ovarian tumors, known as ascites, helps cancer cells survive and spread. Researchers discovered that a decades-old cholesterol drug, bezafibrate, can disrupt this protection by altering fat storage and iron control, making cancer cells more vulnerable to existing treatments.
A new research paper presents a practical diagnostic approach for detecting high-grade serous ovarian carcinoma using a low-cost, portable color sensor device. The method tracks inorganic phosphate generated during nucleic acid amplification, producing a visible green signal that correlates with the amount of amplified DNA.
Researchers found that melatonin increased vascularization and reduced apoptosis in ovarian grafts, improving their viability. The study used an absorbable sponge to apply melatonin to autologous ovarian tissue transplants in rats, revealing its potential as a treatment option for fertility preservation in young cancer patients.
A rare case of mucinous ovarian carcinoma was reported in a postmenopausal woman, initially misdiagnosed as a pelvic abscess due to nonspecific symptoms and radiologic features. The diagnosis was confirmed after advanced imaging and tumor marker assessment. Early recognition is crucial for timely diagnosis and effective treatment of th...
A phase I clinical trial found that QLS5132 demonstrated an objective response rate of 50% and a disease control rate of 94.4% in patients with late-stage, platinum-resistant ovarian cancer. The study also showed a favorable safety profile for the treatment.
Ovarian cancer cells induce adipose tissue dysfunction and ADSC senescence, creating favorable conditions for tumor metastasis. Targeting senescent ADSCs with dasatinib plus quercetin or resveratrol achieves remarkable efficacy in delaying tumor progression and reducing metastases.
Researchers found that adding letrozole to a standard IVF hormone protocol improves live birth in women who respond poorly to ovarian stimulation, producing higher proportions of mature eggs and high-quality embryos.
ISM6200 is a potent, potentially best-in-class preclinical candidate targeting NR3C1 for the treatment of ovarian cancer, Hypercortisolism (Cushing’s Syndrome), and other disorders related to excess cortisol. The molecule demonstrates low DDI risks and higher in vivo efficacy across multiple animal models.
A redesigned endoscope, called CAFE, offers a new way to detect early signs of ovarian cancer by combining high-resolution imaging with gentle cell collection. The device successfully imaged fallopian tube tissue and collected large numbers of epithelial cells, suggesting its potential for earlier disease detection.
A study of over 2,300 North Carolina women with ovarian cancer found that both quick and delayed diagnoses had worse survival rates than those diagnosed in the middle. Considering patient severity may improve outcomes for some symptomatic patients.
A novel method for monitoring on-treatment disease burden in high-grade serous ovarian cancer uses tumor-informed breakpoints-spanning ddPCR, detecting superior sensitivity and specificity compared to real-time PCR. The approach may enable sensitive and specific detection of minimal residual disease and early relapse detection.
Researchers at UC San Diego discover a new way to re-educate the immune system to attack ovarian cancer tumors by blocking protein FAK. The study offers hope for developing better treatments by turning the tumor environment from immune-suppressing to immune-activating.
A new study reveals that fecal transplants from older female mice significantly improve ovarian function and fertility in young mice. The transplants show a direct link between the gut microbiome and ovarian health, with potential implications for fertility and overall health as women age.
Renowned cancer clinician Dr. Daniela Matei will lead the Houston Methodist Dr. Mary and Ron Neal Cancer Center, bringing expertise in ovarian cancer treatment and therapeutics. She aims to bridge laboratory science to the clinic, advancing new concepts from bench to bedside.
Researchers at Linköping University have developed an AI-boosted electronic nose that can detect ovarian cancer from blood plasma samples with high accuracy. The method uses machine learning to identify patterns specific to the disease, making it a promising tool for early detection and improved survival rates.
Researchers discover that finerenone can activate dormant eggs in women with POI, restoring fertility. The study found significant improvement in follicle development and maturation.
Researchers discovered that combining brigatinib with PARP inhibitors is more effective in killing ovarian cancer cells by blocking their survival response. Brigatinib targets key signaling molecules FAK and EPHA2, which aggressive ovarian cancer cells rely on to survive.
A Phase II study presents significant overall survival benefits for women with platinum-resistant ovarian cancer treated with elenagen plus gemcitabine. Longer exposure to elenagen correlates with longer survival after treatment discontinuation, suggesting a fundamentally different therapeutic approach.
Ovarian cancer cells recruit protective mesothelial cells in abdominal fluid to form hybrid cell clusters that resist chemotherapy. These clusters use spike-like structures called invadopodia to invade surrounding tissue. The discovery opens new treatment possibilities and could help doctors monitor disease progression.
A new study confirms that opportunistic salpingectomy (OS), which involves removing fallopian tubes during hysterectomy or tubal ligation, reduces the risk of serous ovarian cancer by nearly 80%. The procedure leaves ovaries intact, preserving hormone production and minimizing side effects.
Melanie Rutkowski's pioneering research may lead to novel immunotherapy treatments for ovarian cancer by understanding how faulty cellular signaling interacts with the microbiome. The grant aims to enhance immune system's ability to kill cancer cells and improve patient outcomes.
Researchers found that ovarian cancer transforms the omentum into an environment that favors tumor spread. The study analyzed tissue samples from 15 patients and created a cell atlas of the omentum in diseased and healthy states.
A new study validates OVCAR3 as a reliable model for high-grade serous ovarian carcinoma, providing insights into disease behavior and potential therapeutic targets. The research also explores the effects of repurposed drugs on ovarian cancer cells, revealing promising results for treatment responses.
Lab studies found that a combination of THC and CBD kills ovarian cancer cells without harming healthy cells. The compounds may prevent metastasis and have minimal toxic effects, making them a promising alternative to current treatments.
This study identifies CLK1 as a key player in PARPi resistance and demonstrates that its inhibition can restore PARPi sensitivity in ovarian cancer. By targeting CLK1, researchers aim to develop a new therapeutic strategy for overcoming PARPi resistance.
A 20-year study analyzed 39 cases of primary ovarian leiomyoma, a rare type of benign tumor that develops in the ovary. The study highlights the limitations of imaging in diagnosing these tumors and emphasizes the importance of precise diagnostic methods.
Sofetabart mipitecan, a novel ADC targeting folate receptor alpha, shows robust clinical activity in patients with platinum-resistant ovarian cancer. The GOG-3133/ FRAmework-01 phase 3 study aims to expand treatment options for recurrent ovarian cancer and address the need for more effective therapies.
Researchers at CU Anschutz have discovered a novel therapy combination to offer new hope to ovarian cancer patients who do not respond to existing treatments. The combination of a PARP inhibitor and SM08502 boosts the effectiveness of treatment, even for patients resistant to PARP inhibitors.
A UTEP research team found that Claudin-4, a protein increasing in ovarian cancer, may help tumors survive and hide from the immune system. Targeting Claudin-4 with a peptide and PARP inhibitor slows tumor growth and enhances the immune system's ability to fight cancer.
Australian scientists have developed a new blood test that can identify women with ovarian cancer more likely to benefit from PARP inhibitor therapy, offering hope for more effective treatment. The test measures immune biomarkers and predicts which patients will respond to treatment.
MIT researchers have developed new nanoparticles that deliver the immune-stimulating molecule IL-12 directly to ovarian tumors, eliciting a strong response and clearing tumors in over 80% of mice. This treatment combines with checkpoint inhibitors to launch an attack on cancer cells without causing side effects.
Scientists have identified a new biomarker, F2R, which could improve ovarian cancer diagnosis and treatment. Elevated F2R levels are associated with shorter life spans, making it a valuable prognostic indicator.
MSK researchers have developed a new method to study treatment resistance in high-grade serous ovarian cancer. By analyzing blood samples from 18 patients, they identified subpopulations of cancer cells with distinctive genetic features that contribute to recurrence. This approach may help develop targeted treatments for specific vulne...
The loss of Trp53 leads to more aggressive tumor growth and weaker immune responses in ovarian cancer. Researchers developed a mouse model that mimics human HGSC, showing how the disease progresses and evades the immune system.
Researchers identified NBL1 as a key driver of ovarian cancer metastasis through its activation of the Jak/Stat3 pathway. NBL1 expression levels strongly correlated with advanced clinical stage and poor survival outcomes.
Researchers developed Ovatools, a tool combining blood test results and age to identify women at higher risk of ovarian cancer. The approach is accurate for women over 50 and represents good value for the NHS, detecting more cancers earlier while remaining within affordability thresholds.
Researchers at Rice University developed a mathematical model that sheds light on ovarian aging and menopause timing. The study reveals synchronized and predictable patterns of follicle depletion, accelerating during midlife, which helps explain why menopause typically occurs at similar ages for most women.
Researchers developed a comprehensive road map of ovarian reserve formation in primates, providing crucial insights into women's health. The study could lead to better treatments for infertility and hormonal disorders like PCOS.
Extracellular vesicles play a crucial role in regulating oocyte maturation, follicular growth, and quality. In pathological conditions, EVs can disrupt communication, leading to impaired oocyte development and ovarian failure. Therapeutic EVs show promise in reversing ovarian pathologies by delivering functional molecules.
A 36-year-old woman was diagnosed with non-gestational ovarian choriocarcinoma, a rare and aggressive tumor that shares symptoms with pregnancy. She received chemotherapy and showed complete response to treatment.
Dynamin 1 regulates EMT progression, cell polarity and migration through N-cadherin endocytosis and recycling, promoting ovarian cancer metastasis. The study identifies DNM1 as a critical regulator of EMT-associated metastasis.
A 23-year bibliometric analysis reveals key hotspots in ovarian cancer care, including quality of life, surgery, and nursing health. The study emphasizes the need for future research on psychological well-being and integrated care models to improve outcomes for women with ovarian cancer.
Researchers developed a novel radioimmunotherapy that successfully eliminated cancer stem cells (CSCs) in preclinical models of ovarian cancer. The therapy, targeting CSC-associated biomarkers L1CAM + /CD133 + , showed significantly increased cytotoxicity compared to existing treatments.
A study of ovarian tumor immune landscapes reveals four distinct immunologic subtypes, with those with T cells surviving longer and having better outcomes. The researchers also found that myeloid cells play a key role in reestablishing the immune landscape upon recurrence.
Researchers evaluated the Stem Cell Regenera treatment in 145 women with ovarian failure, showing nearly 70% oocyte activation and 14% conception through IVF after treatment. The therapy stimulates ovarian activity, increasing conception chances in selected patients.
A team led by University of Houston engineer Tianfu Wu aims to find better biomarkers for ovarian cancer using autoantibodies and machine learning. By detecting ovarian cancer earlier, mortality rates could be reduced by 10-30%.
A new study found that over 65% of ovarian cancer tumors exhibit whole-genome doubling, making them more resistant to treatments. WGD-high tumors suppress the immune response by repressing key pathways.
Researchers discovered that psychological stress activates the NR3C1/NUPR1 axis, accelerating ovarian tumor metastasis through epithelial-mesenchymal transition. Elevated NR3C1 positively correlates with NUPR1 expression and poorer prognosis in ovarian cancer patients.
A new combination treatment strategy selectively targets ovarian tumor cells, reducing growth in preclinical models. The approach identifies effective regimens to treat genetically diverse cancers by blocking specific growth signaling pathways.
Researchers identify XPR1 as critical factor in promoting ovarian cancer aggressiveness through autophagy regulation and MHC-I expression. The study suggests targeting XPR1 alongside autophagy inhibition to improve immunotherapy outcomes in ovarian cancer.